Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 441-448

  Pont, J ^a   Albrecht, W ^a   Postner, G ^a   Sellner, F ^a   Angel, K ^a   Holtl W ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GERM CELL TUMOR; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL;

EID: 0030045568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.441     Document Type: Article

References (45)

1. Fung CY, Garnick MB: Clinical stage I carcinoma of the testis: A review. J Clin Oncol 6:734-750, 1988
2. Gressler VH, Levine LA, Vogelzang NJ: A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor? J Clin Oncol 8:4-8, 1990 (editorial)
3. Rorth M, Jacobson GK, von der Maase H, et al: Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 9:1543-1548, 1991
4. von Eschenbach AC, Gleave ME, Swanson DA: Conservative management of the retroperitoneum for stages I and II nonseminomatous germ cell tumors. World J Urol 10:43-48, 1992
5. Donohue JP, Thornhill JA, Foster RS, et al: Stage I nonseminomatous germ-cell testicular cancer - Management options and risk-benefit considerations. World J Urol 12:170-177, 1994
6. Höltl W, Kosak D, Pont J, et al: Testicular cancer: Prognostic implications of vascular invasion. J Urol 137:683-685, 1987
7. Freedman LS, Jones WG, Peckham MJ, et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 2:294-298, 1987
8. Dunphy CH, Ayala AG, Swanson DA, et al: Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 62:1202-1206, 1988
9. Fung CY, Kalish LA, Brodsky GL, et al: Stage I nonseminomatous germ cell testicular tumor: Prediction of metastatic potential by primary histopathology. J Clin Oncol 6:1467-1473, 1988
10. Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study. J Clin Oncol 8:509-518, 1990
11. Read G, Stenning SP, Cullen NH, et al: Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10:1762-1768, 1992
12. Colls BM, Harvey VJ, Skelton L, et al: Results of the surveillance policy of stage I nonseminomatous germ cell testicular tumors. Br J Urol 70:423-428, 1992
13. Sturgeon JFG, Jewett MAS, Alison RA, et al: Surveillance after orchiectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10:564-568, 1992
14. Sesterhenn IA, Weiss RB, Mostofi FK, et al: Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup Study. J Clin Oncol 10:69-78, 1992
15. Pont J, Höltl W, Kosak D, et al: Risk-adapted treatment choice in stage I non-seminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: A prospective trial. J Clin Oncol 8:16-20, 1990
16. Hermanek P, Sobin LH (ed): TNM Classification of Malignant Tumors (ed 4). New York, NY, Springer, 1987
17. Miller AB, Hoogstraten B, Stacquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-36, 1976
19. Quanjer PH: Standardized lung function testing. Bull Eur Physiopathol Respir 19:1-95, 1983
20. World Health Organization: WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction. Cambridge, United Kingdom, Cambridge Press, 1987
21. Schaefer SD, Post JD, Close LG, et al: Ototoxicity of low-and moderate-dose cisplatin. Cancer 56:1934-1939, 1985
22. Sandeman TF, Yang C: Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 62:1471-1475, 1988
23. Oliver RTD, Raja MA, Ong J, et al: Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148:1453-1456, 1992
24. Studer UE, Fey MF, Calderoni A, et al: Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 23:444-449, 1993
25. Cullen MH, Stenning SP, Parkinson MC, et al: Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis (NSGCTT): An MRC(UK) study report. Proc Am Soc Clin Oncol 14:244, 1995 (abstr 650)
26. Bosl GJ: The late effects of germ cell tumor chemotherapy: More data are needed. J Clin Oncol 10:1375-1376, 1992
27. Fossa SD, Aass N, Kaalhus O, et al: Long-term survival and morbidity in patients with metastatic malignant germ cell tumours treated with cisplatin based combination chemotherapy. Cancer 58:2600-2650, 1986
28. Roth BJ, Greist A, Kubilis PS, et al: Cisplatin-based combination chemotherapy for disseminated germ cell tumours. Long term follow-up. J Clin Oncol 6:1239-1247, 1988
29. Stoter G, Koopman A, Cornelis PJ, et al: Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine and bleomycin. J Clin Oncol 7:1099-1104, 1989
30. Boyer M, Raghavan D, Harris PJ, et al: Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8:21-26, 1990
31. Osanto S, Bukman A, Van Hoek F, et al: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10:574-579, 1992
32. Dearnaley DP, Horwich A, A'Hern R, et al: Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up. Eur J Cancer 27:684-691, 1991
33. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992
34. Ellis PA, Fitzharris BM, George PM, et al: Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. J Clin Oncol 10:1609-1614, 1992
35. Nichols CR, Roth BJ, Williams DS, et al: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10:760-765, 1992
36. Aass N, Fossa SD, Theodorsen L, et al: Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 27:1087-1091, 1991
37. Hansen SW, Berthelsen JG, von der Maase H: Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine and bleomycin versus surveillance. J Clin Oncol 8:1695-1698, 1990
38. Petersen PM, Hansen SW, Giwercman A, et al: Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5:355-358, 1994
39. Senturia YD, Peckham CS: Children fathered by men treated with chemotherapy for testicular cancer. Eur J Cancer 26:429-432, 1990
40. Bisset D, Kunkeler L, Zwanenburg L, et al: Long-term sequelae of treatment for germ cell tumours. Br J Cancer 62:655-659, 1990
41. Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al: Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 11:415-424, 1993
42. Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
43. Travis LB, Curtis RE, Hankey BF: Second malignancies after testicular cancer. J Clin Oncol 13:533-534, 1995 (letter)
44. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al: Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338:359-363, 1991
45. Boshoff C, Begent RHJ, Oliver RTD, et al: Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 6:35-40, 1995